Skip to main content
Changzhou Qianhong Bio-pharma Co.,Ltd logo

Changzhou Qianhong Bio-pharma Co.,Ltd — Investor Relations & Filings

Ticker · 002550 ISIN · CNE100001070 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,298 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002550

About Changzhou Qianhong Bio-pharma Co.,Ltd

https://www.qhsh.com.cn

Changzhou Qianhong Bio-pharma Co.,Ltd. specializes in the research, development, and manufacturing of biochemical medicines. The company focuses on two primary product categories: heparin series and enzyme series. Its heparin portfolio includes Heparin Sodium, Enoxaparin Sodium, and Dalteparin Sodium, which are utilized as anticoagulants and antithrombotics. The enzyme series features Pancreatic Kallidinogenase for microcirculation improvement and Asparaginase for oncology applications. Qianhong Bio-pharma maintains an integrated production model, covering the entire process from raw material extraction to finished dosage forms. The company adheres to international quality standards and supplies active pharmaceutical ingredients (APIs) and finished preparations to global markets, emphasizing therapeutic solutions for cardiovascular, cerebrovascular, and metabolic diseases.

Recent filings

Filing Released Lang Actions
关于常州千红生化制药股份有限公司申请向不特定对象发行可转换公司债券的补充法律意见书之二
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the application of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. to issue convertible corporate bonds to unspecified investors. It references various legal and regulatory compliance aspects, including company law, securities law, and management regulations. The document includes detailed legal analysis, verification of company qualifications, shareholder information, and compliance with issuance conditions. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it pertains to the issuance of convertible bonds and related legal opinions and approvals.
2026-05-26 Chinese
公证天业会计师事务所（特殊普通合伙）关于常州千红生化制药股份有限公司可转债申请文件的反馈意见的回复
Capital/Financing Update Classification · 85% confidence The document is a detailed response to a Shenzhen Stock Exchange review inquiry (“审核问询函”) concerning the company’s application to issue convertible bonds to unspecified investors and list them on the main board. It pertains directly to a capital-raising transaction (convertible bond issuance) and contains extensive financial data and explanatory disclosures for the financing application. This falls under updates on company fundraising and financing activities – Capital/Financing Update (CAP).
2026-05-26 Chinese
关于常州千红生化制药股份有限公司申请向不特定对象发行可转换公司债券的审核问询函的回复
Regulatory Filings Classification · 86% confidence The document is a formal reply (“审核问询函的回复”) to an inquiry issued by the Shenzhen Stock Exchange concerning the company’s application to issue convertible bonds to unspecified investors. It contains detailed regulatory responses and supplemental information rather than being an actual financial report (e.g., annual or interim report), earnings release, management presentation, or a change in management announcement. It is part of the compliance and review process for a bond issuance, making it a general regulatory submission that does not fit a more specific category. As such, it falls under the fallback category Regulatory Filings (RNS).
2026-05-26 Chinese
关于常州千红生化制药股份有限公司申请向不特定对象发行可转换公司债券的补充法律意见书之三
Capital/Financing Update Classification · 85% confidence The document is a detailed legal opinion letter issued by Beijing Grandway Law Offices regarding Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.’s application to issue convertible bonds to unspecified investors. It is part of the bond issuance process and contains substantive legal analysis, responses to the exchange’s inquiry letter, and exhaustive verification procedures. This is not a general regulatory announcement (RNS) nor an annual/interim report, but rather relates directly to a financing event (the proposed convertible bond issuance). Therefore, it falls under the “Capital/Financing Update” category (CAP).
2026-05-26 Chinese
关于常州千红生化制药股份有限公司向不特定对象发行可转换公司债券并在主板上市之发行保荐书
Capital/Financing Update Classification · 90% confidence The document is a detailed sponsor’s underwriting prospectus (“发行保荐书”) for a Chinese listed company’s convertible bond issuance to unspecified investors and listing on the main board. It outlines the bond issuance terms, legal and regulatory compliance, underwriting procedures, internal approvals, and bond covenants—not a financial report, management change, or general regulatory announcement. This clearly constitutes a financing activity update. Hence it should be classified as a Capital/Financing Update.
2026-05-26 Chinese
关于向不特定对象发行可转换公司债券的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 90% confidence The document is an announcement detailing the company’s response to the Shenzhen Stock Exchange review inquiries and updates to its application/prospectus for issuing convertible corporate bonds to unspecified investors. It focuses on financing activities and capital structure changes (convertible bond issuance), which aligns with the Capital/Financing Update category.
2026-05-26 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.